Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CRM
IHD
Cosentyx® - Anti IL-17
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03769168 (CAIN457F2304E1 - extension study)
Psoriatic arthritis
Phase 3
64
Number of participants with JIA ACR30 response
Secukinumab 75 mg/0.5 ml
Secukinumab 150 mg/1.0 ml
Patients with juvenile idiopathic arthritis subtypes of juvenile psoriatic arthritis and
enthesitis related arthritis
Target Patients
Read-out Milesstone(s)
2025
Publication
TBD
NCT04156620 INVIGORATE-1 (CAIN457P12301)
Axial spondyloarthritis
Phase 3
500
The proportion of subjects achieving an ASAS40 (Assessment of SpondyloArthritis
International Society criteria) response
Secukinumab intravenous (i.v.) regimen
Placebo intravenous (i.v.) regimen
Patients with active axial spondyloarthritis
Primary (week 16): 2022; Final: 2023
2023
77 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation